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SUMMARY
The regulation of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) trafficking af-
fects multiple brain functions, such as learning and memory. We have previously shown that Thorase plays
an important role in the internalization of AMPARs from the synaptic membrane. Here, we show that
N-methyl-D-aspartate receptor (NMDAR) activation leads to increased S-nitrosylation of Thorase and
N-ethylmaleimide-sensitive factor (NSF). S-nitrosylation of Thorase stabilizes Thorase-AMPAR complexes
and enhances the internalization of AMPAR and interaction with protein-interacting C kinase 1 (PICK1).
S-nitrosylated NSF is dependent on the S-nitrosylation of Thorase via trans-nitrosylation, which modulates
the surface insertion of AMPARs. In the presence of the S-nitrosylation-deficient C137L Thorase mutant,
AMPAR trafficking, long-term potentiation, and long-term depression are impaired. Overall, our data suggest
that both S-nitrosylation and interactions of Thorase and NSF/PICK1 are required to modulate AMPAR-
mediated synaptic plasticity. This study provides critical information that elucidates the mechanism under-
lying Thorase and NSF-mediated trafficking of AMPAR complexes.
INTRODUCTION
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid recep-
tors (AMPARs), which are enriched in the postsynaptic mem-
brane on dendritic spines, are highly dynamic, and cycling in
and out of the postsynaptic membrane is thought to regulate
synaptic plasticity (Asrar and Jia, 2013; Bassani et al., 2009;
Chater and Goda, 2014). Changes in the expression levels of
AMPARs, subunit composition, andmodifications of their acces-
sory proteins have been shown to mediate synaptic strength.
The AMPAR subunit, GluA2, plays critical roles in synaptic plas-
ticity by influencing AMPAR assembly and trafficking, which is
fundamentally important for learning, memory formation, and
storage (Dong et al., 1997; Tan et al., 2015). Dysregulation of
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GluA2 on the postsynaptic membrane expression has been
implicated in various pathological states and has important con-
sequences for several brain disorders, such as epilepsy, Alz-
heimer disease, Parkinson disease, and schizophrenia (Beneyto
andMeador-Woodruff, 2006; Corti et al., 2011; Pøhlsgaard et al.,
2011). AMPAR-containing-GluA2s (AMPAR-GluA2) are main-
tained at the surface of synapses by postsynaptic density
(PSD) proteins such as glutamate receptor interacting protein 1
(GRIP1) (Menniti et al., 2013). Other PSD proteins such as N-eth-
ylmaleimide-sensitive factor (NSF) and protein-interacting C
kinase 1 (PICK1) have been shown to modulate the trafficking
of AMPAR-GluA2 (Arendt et al., 2015; Li et al., 2016). Despite
the extensive studies on AMPAR trafficking, the mechanisms
that control AMPAR-mediated synaptic plasticity and how NSF
regulate recycling of intracellular AMPAR-GluA2 remain unclear.
Thorase, a PSD protein, is a AAA+ ATPase that plays a critical
role in synaptic plasticity by modulating the recycling and traf-
ficking of AMPAR-GluA2 (Ahrens-Nicklas et al., 2017; Piard
et al., 2018; Prendergast et al., 2014; Umanah et al., 2017; Zhang
et al., 2011). Thorase has also been shown to be neuroprotective
(Dai et al., 2010; Pignatelli et al., 2017; Umanah et al., 2017;
Zhang et al., 2011). The loss of Thorase decreases the internali-
zation of AMPARs, resulting in increased post-synaptic receptor
density. The disassembly of the GluA2-GRIP1 complex, which is
critical for the internalization of AMPAR-GluA2, is mediated by
Thorase (Ahrens-Nicklas et al., 2017; Piard et al., 2018; Prender-
gast et al., 2014; Umanah et al., 2017; Zhang et al., 2011). Thus,
Thorase plays a critical role in modulating AMPAR-mediated
neurotransmission. However, the precise mechanisms by which
Thorase mediates AMPAR complex disassembly and internali-
zation remain to be elucidated. The intracellular signaling that
controls Thorase-mediated internalization of GluA2 in response
to N-methyl-D-aspartate receptor (NMDAR) activation is not
known. Here, we show that S-nitrosylation of Thorase following
NMDAR activation inhibits ATP binding and ATP hydrolysis, re-
sulting in the stabilization of the GluA2/GRIP1 complex and
also facilitating AMPAR-GluA2 internalization. Furthermore,
S-nitrosylated Thorase transnitrosylates NSF, and in the
process, the GluA2/GRIP1 complex disassociates, allowing
S-nitrosylated NSF to bind to AMPAR-GluA2 and insert into
the postsynaptic membrane. Our study provides insight into
the mechanisms by which S-nitrosylation of Thorase and NSF
and their interactions with AMPAR-GluA2 complexes modulate
AMPAR-mediated neurotransmission and synaptic plasticity.
RESULTS
Thorase Is S-Nitrosylated
To determine whether Thorase is S-nitrosylated, the biotin
switch assay (Jaffrey and Snyder, 2001) was conducted on re-
combinant Thorase. Treatment with the nitric oxide (NO) donor
S-nitrosoglutathione (GSNO) S-nitrosylates Thorase, whereas
glutathione (GSH) has no effect (Figures 1A and 1B). To ascertain
the specific cysteine residues involved in the S-nitrosylation of
Thorase, mass spectrometric analysis was performed on Thor-
ase treated with GSNO (Doulias et al., 2010, 2013). The results
indicated that Thorase is S-nitrosylated on C137 and C310
residues (Figure S1A). To confirm that C137 and C310 are
the residues for S-nitrosylation of Thorase, C137 and C310
residues were mutated to serine. Both wild-type (WT) and
Figure 1. S-Nitrosylation of Thorase at Res-
idue C137 Inhibits ATPase Activity
(A) Immunoblot analyses of S-nitrosylation of
Thorase with GSNO and control GSH.
(B) Graphical representation of the percentage of
S-nitrosylated Thorase (n = 4, p % 0.0001).
(C) A 3D model of Thorase ATPase domain
showing C137, K139, and E193 location in the ATP
catalytic site.
(D) Multiple alignments of Thorase (ATAD1) ho-
mologs showing conserved C137 (red text).
(E) Immunoblot analyses of S-nitrosylation of
Thorase wild type (WT), C137L, and C310S.
(F) Graphical representation of the relative amount
of S-nitrosylated Thorase compared to control,
GSH (n = 3, p % 0.0001).
(G and H) ATPase analyses of Thorase WT and
C137L in the presence of GSH and GSNO (n = 4,
p = 0.0002). The ATPase activity in the presence of
GSH was considered 100% activity.
(I and J) ATP binding activities of Thorase WT and
C137L in the presence of GSH and GSNO. GSNO
inhibits WT but not C137L ATPase activity (n = 3,
p = 0.0036).
Means ± standard errors of the mean (SEMs) of the
experiments performed. *p < 0.10, **p < 0.05,
***p < 0.01, n.s., p > 0.10; ANOVA with Holm-Sidak
post hoc test compared with WT; power: 1-b error
probability = 0.9–1.0.




C310S recombinant Thorase are S-nitrosylated, whereas
S-nitrosylation of C137S Thorase is profoundly reduced (Figures
S1B and S1C). These data demonstrate that C137 is the main
site for the S-nitrosylation of Thorase. A 3D prediction model of
the ATPase domain of Thorase (Figure 1C) suggests that C137
is in close proximity to Walker A residue, K139 (ATP binding)
and Walker B residue E193 (ATP hydrolase/ATPase). The multi-
ple alignment of Thorase homologs (Figure 1D) suggests that
C137 is conserved in the AAA ATPase domain among the homo-
logs. Substitution of C137 with serine shows defects in ATP
hydrolysis, while Cys310 substitution with serine has no effect
(Figures S1D and S1E). Therefore, Cys137 was mutated to
alanine, leucine, aspartate, and serine and ATP hydrolysis was
evaluated (Figures S1F and S1G). The mutation of C137 to
alanine (C137A) or leucine (C137L) had no effect on ATP hydro-
lysis. Since the C137L had similar ATPase activity to WT, it was
used for this study. The biotin switch assay confirms that C137L
is not S-nitrosylated (Figures 1E and 1F). GSNO S-nitrosylation
of WT Thorase inhibits both ATP binding and ATP hydrolysis,
whereas GSNO has no effect on C137L Thorase, similar to the
effect of GSH on WT Thorase (Figures 1G–1J).
NMDA Induced S-Nitrosylation of Thorase
To determine whether Thorase is endogenously S-nitrosylated,
WT or nNOS knockout (KO) primary neurons were stimulated
with 20 mM NMDA and 10 mM glycine (Figures 2A and 2B). Thor-
ase is S-nitrosylated within the first minute of NMDA/glycine
Figure 2. In Vivo S-Nitrosylation of Thorase
Inhibits Oligomer Disassembly
(A) Immunoblot analyses of NMDA-stimulated S-
nitrosylation of Thorase in WT and nNOS KO
neurons. S-nitrosylation of Thorase was assessed
at different times after NMDA treatment of neu-
rons.
(B) Graphical representation of relative amount of
S-nitrosylated Thorase (n = 3, p % 0.0001).
(C and D) Immunoblot analyses of NMDA-stimu-
lated (5 min) S-nitrosylation of Thorase in WT pri-
mary neurons treated with MK-801 (n = 4, p %
0.0001).
(E and F) Immunoblot analyses of NMDA-stimu-
lated S-nitrosylation of Thorase in WT primary
neurons treated with L-NAME (n = 4, p % 0.0001).
(G) Immunoblot analyses of Thorase WT and mu-
tants E193Q and C137L ATP-dependent oligomer
formation in the presence of GSH or GSNO with
ADP, ATP, or ATPgS.
(H) Graphical representation of percentage of
Thorase oligomer in (G) (n = 3, p % 0.0001).
Means ± SEMs of the experiments performed.
**p < 0.05, ***p < 0.01, n.s. p > 0.10; ANOVA with
Holm-Sidak post hoc test compared with WT;
power: 1-b error probability = 0.9–1.0.
stimulation and levels are maintained
for 5 min, with a slow decrease over
the following 60 min in WT neurons.
NMDA/glycine stimulation fails to S-nitro-
sylate Thorase in neuronal NO synthase
(nNOS) KO neurons (Figures 2A and 2B). To confirm that endog-
enous S-nitrosylation of Thorase is NMDAR and nNOS depen-
dent, WT cultures were stimulated with NMDA/glycine in the
presence of the NMDA antagonist, MK801, or the NOS inhibitor
L-NG-nitroarginine methyl ester (L-NAME). MK801 or L-NAME
significantly inhibited the S-nitrosylation of Thorase (Figures
2C–2F).
S-Nitrosylation of Thorase Inhibits Oligomer
Disassembly
We evaluated the assembly and disassembly of Thorase in the
presence of ATP using chemical crosslinking, as previously
described (Babst et al., 1998). The binding of non-hydrolyzable
ATP (Figure 2G, ATPgS) to WT Thorase facilitates oligomer as-
sembly and ATP hydrolysis (Figure 2G; ATP-GSH) disassembles
the oligomer, as indicated by a change in the ratio of oligomeric
to monomeric Thorase (Figure 2H). The ATP hydrolysis-deficient
Walker B Thorase mutant (E193Q) is not responsive to ATP hy-
drolysis-mediated oligomeric disassembly (Figures 2G and
2H). To ascertain whether NO regulates the disassembly of Thor-
ase oligomers, the disassembly assay was performed in the
presence of GSNO on recombinant WT or C137L Thorase.
GSNO significantly reduces the disassembly of WT from the
oligomeric to the monomeric form, but it has no effect on the
C137L mutant (Figures 2G and 2H). The results suggest that
S-nitrosylation of Thorase impairs the disassembly of the
Thorase oligomeric complex.




The Disassembly of the GRIP1/GluA2 Complex Is
Inhibited by S-Nitrosylation of Thorase
Thorase disassembles the GluA2/GRIP1 complex in an ATP-
dependent manner (Umanah et al., 2017; Zhang et al., 2011).
We therefore determined the effects of NO on Thorase-medi-
ated disassembly of the GluA2/GRIP1 complex. As previously
reported (Umanah et al., 2017; Zhang et al., 2011), GluA2,
GRIP1, and Thorase co-exist as a complex (Figure 3A). The
binding of GRIP1 and Thorase to the GluA2 complex is sensi-
tive to ATP hydrolysis since there is less binding in the pres-
ence of hydrolyzable ATP (ATP) and elevated in the presence
of the non-hydrolyzable form of ATP (ATPgS), compared to
ADP-treated samples (Figures 3A–3C). GSNO significantly re-
duces the disassembly of GRIP1 from GluA2. GSNO has no
effect on C137L Thorase-mediated disassembly of GRIP1
from GluA2 (Figures 3B and 3C). Thus, the S-nitrosylation of
Thorase inhibits the disassembly of Thorase-GRIP1-GluA2
complex.
S-Nitrosylation of Thorase Is Important for Endocytosis
of GluA2
An antibody-feeding internalization assay was used to evaluate
the role of S-nitrosylation of Thorase in endocytosis of surface
GluA2. Thorase KO primary neurons were transduced with lenti-
viral WT or C137L mutant GFP-tagged Thorase. Live neurons
were incubated with an anti-GluA2 N-terminal antibody followed
by treatment with NMDA/glycine to induceGluA2 endocytosis. In
control unstimulated cultures, an increased surface expression
of GluA2 in neurons expressing control GFP or Thorase-GFP
C137L mutant as compared to Thorase-GFP WT is observed
(Figures 3D–3F). Moreover, a significant internalization of
surface GluA2 in Thorase WT neurons in response to NMDA
is detected, while neurons expressing GFP or Thorase
C137L mutant display significantly less internalization of surface
GluA2 (Figure 3E). In response to NMDA/glycine, the ratio of
surface GluA2:intracellular GluA2 is significantly decreased in
neurons expressing Thorase WT, while neurons expressing
Thorase mutants have a significantly increased ratio of surface
GluA2:intracellular GluA2 consistent with a defect in AMPAR
endocytosis (Figure 3F).
The effects of Thorase S-nitrosylation on GluA2 surface
expression was also assessed by a bis(sulfosuccinimidyl)-sub-
erate (BS3) crosslinking assay that allows for the quantification
of surface and intracellular receptor pools (Conrad et al., 2008).
In unstimulated Thorase KO primary neurons and cultures ex-
pressing the Thorase C137L mutant, the ratio of surface
GluA2:intracellular GluA2 is increased compared to Thorase
WT-expressing cultures (Figures 3G and 3H). In response to
NMDA/glycine the ratio of surface GluA2:intracellular GluA2 is
significantly decreased in neurons expressing Thorase WT,
while Thorase KO neurons and Thorase C137L neurons have
a significantly increased ratio of surface GluA2:intracellular
GluA2 consistent with a defect in AMPAR endocytosis
(Figure 3H).
Figure 3. S-Nitrosylation of Thorase Is Crit-
ical for Endocytosis of GluA2
(A) Immunoblot analyses of GluA2 immunopre-
cipitation (IP) from neurons expressing Thorase
WT or C137L in the presence of GSH or GSH with
ADP, ATP, or ATPgS.
(B and C) Graphical representation of relative
percentage of GRIP1 and Thorase disassembled
from GluA2 (n = 3, p = 0.0015).
(D) Representative images of unstimulated or
NMDA-induced endocytosis of GluA2 in neurons
expressing GFP, Thorase-GFP WT, or C137L
mutant. Image scale bar high resolution, 20 mm;
low resolution, 2 mm.
(E) Quantification of the ratio of surface GluA2
(sGluA2) to internalizedGluA2 (iGluA2) for (n = 3 per
replicate, p = 0.0100).
(F) GluA2 internalization index shown in (D) as
measured as the ratio of iGluA2 to the total GluA2
(iGluA2 plus sGluA2) fluorescence intensities (n = 3
per replicate, p = 0.0110).
(G) Immunoblot analyses of BS3-crosslinking of
sGluA2 in Thorase KO neurons expressing Thor-
ase WT or C137L mutant.
(H) The optical densitometry quantification of
sGluA2 for (F) (n = 3, p = 0.0029).
Means ± SEMs of the experiments performed. *p <
0.10, n.s. p > 0.10; ANOVA with Holm-Sidak post
hoc test compared with WT; power: 1-b error
probability = 0.9–1.0.





Thorase, NSF, and PICK1
The elevated levels of surface GluA2 and defects in endocytosis
in the presence of the Thorase C137L mutant suggests that the
S-nitrosylation of Thorase may influence the activities of other
PSD proteins that are involved in the insertion of GluA2 during
AMPAR trafficking. We have suggested that Thorase and NSF
may exist in a complex with GluA2 (Prendergast et al., 2014).
To further determine the interactions of Thorase-NSF-GluA2
Thorase proteins, recombinant glutathione S-transferase
(GST)-tagged Thorase was used to pull down potential Thorase
interactors from whole-brain lysates (Figure 4A). When sepa-
rating protein complexes pulled down by recombinant Thorase
from brain lysates according to their molecular size using fast
protein liquid chromatography (FPLC), we confirmed via immu-
noblotting that GluA1, GluA2, NSF, and Thorase co-exist in
different complexes of high-molecular-weight (FPLC fractions
2–3 in Figure 4B) Thorase-NSF complex in fraction 4, with the
Thorase-PICK1 complex in fractions 5 and 6. The potential inter-
action of Thorase with NSF and GluA2 was further monitored in
the presence of GSH or GSNO. Thorase, GluA2, NSF, and PICK1
were immunoprecipitated from mouse whole-brain lysates (Fig-
ure 4C). Thorase exists in a complex with GluA2 and NSF and
this complex is dissociated in the presence of ATP-GSH (Figures
4C and 4D). GSNO inhibits the dissociation of the GluA2-Thor-
ase-NSF complex. PICK1 interactions with Thorase were also
confirmed in Thorase immunoprecipitated samples and vice
versa. The Thorase-PICK1-GluA2 complex dissociates in the
presence of ATP (GSH) and is inhibited by GSNO (Figures 4C
and 4D).
The phosphorylation states of GluA2, especially GluA2-S880-
phosphorylation (GluA2-S880p), have been shown to influence
the interaction of accessory proteins that regulate the trafficking
of GluA2 (Chung et al., 2000; Kim et al., 2001). We therefore
immunoprecipitated GluA2 (total) and GluA2-S880p frommouse
whole-brain lysates in the presence of GSNO to determine the
binding preferences of Thorase, NSF, PICK1, and GRIP1.
Consistent with a previous study (Lin and Huganir, 2007),
PICK1 associates more with GluA2-S880p and GRIP1 (Figures
4E and 4F), and NSF preferentially binds to the non-phosphory-
lated GluA2 complex. In contrast, Thorase shows no preference
for GluA2-S880p complexes or non-phosphorylatedGluA2 com-
plexes. The presence of GSNO augments NSF binding to GluA2,
but did not influence Thorase binding to GluA2. The presence of
GSNO also inhibits the dissociation of Thorase/PICK1 from the
GluA2-S880p (Figure 4F).
Thorase Interacts Directly with NSF
To determine whether Thorase directly interacts with NSF, re-
combinant GST-Thorase and His6-NSF were examined in GST
pull-down (Figures 4G, 4H, S1H, and S1I). GST-Thorase pulls
down His6-NSF in an ATP-dependent manner (Figures S1H
and S1I). GSNO inhibits the ATP-driven dissociation of GST-
Thorase from His6-NSF, while GSNO has no effect on ATP-
driven dissociation of GST-C137L Thorase from His6-NSF (Fig-
ures 4G and 4H). The interaction of GluA2 with Thorase and
NSF was also evaluated by GST pull-down assays using the
(GST)-tagged C-terminal fragment of GluA2 (GST-GluA2C). In
the presence of GSH, both Thorase (GluA2C/Thor) and NSF
(GluA2/NSF) strongly bind to GST-GluA2C (Figures 4I, 4J, and
S1H–S1J). However, in the presence of equal amounts of Thor-
ase and NSF (GluA2C +NSF + Thor), both display50%binding
to GluA2C, suggesting that both proteins may bind to the same
site on GluA2 C terminus.
We further evaluated the GST-GluA2C pull-down of Thorase
and NSF in the presence of GSH or GSNO. Prebound GluA2C-
Thorase (GluA2C/Thor) and GluA2C-NSF (GluA2C/NSF) com-
plexes were treated with GSH or GSNO. The addition of excess
NSF to GSH and GSNO-pretreated GluA2-Thorase complex
(GluA2C/Thor + NSF) displaced 40% and 42% of Thorase,
respectively, from GluA2C. However, the addition of excess
Thorase to GSH and GSNO-pretreated GluA2-NSF complex
(GluA2C/NSF + Thor) displaced 58% and 40% of NSF, respec-
tively, from GluA2C (Figures 4I, 4J, and S1H–S1J). Thus, S-nitro-
sylation of NSF favors NSF binding to GluA2 over Thorase.
Thorase Transnitrosylates NSF
Previously, we showed that the expression and distribution of
synaptic proteins such as PICK1, NSF, and NMDAR are not
affected by Thorase expression (Pignatelli et al., 2017; Prender-
gast et al., 2014; Zhang et al., 2011). We evaluated the expres-
sion and colocalization of NSF with GluA2 (Figures S1K–S1N)
and did not observe any significant differences between WT
and Thorase KO. The data suggest that the absence of Thorase
does not alter the localization of NSF. Consistent with a previous
study (Huang et al., 2005) NSF is S-nitrosylated by NMDA stim-
ulation in primary neurons (Figures S2A and S2B). However,
in contrast to Thorase S-nitrosylation, which decreases after
NMDA treatment (see Figures 2A and 2B), NSF remains S-nitro-
sylated up to 60 min after NMDA treatment (Figures S1H and
S1I). In addition, the S-nitrosylation of NSF is significantly
reduced in Thorase KO neurons (Figures 5A and 5B). NMDA-
dependent S-nitrosylation of NSF is abolished in nNOS KO
mice (Figures S2C and S2D), as previously reported (Huang
et al., 2005).
To determine whether S-nitrosylated Thorase can transfer its
NO group to NSF, we performed an in vitro S-transnitrosylation
assay. Purified WT Thorase and C137L Thorase were exposed
to GSNO to induce S-nitrosylation, with GSH treatment as a con-
trol. After removing excess GSNO from the sample, the proteins
were incubated with purified NSF, followed by a biotin switch
assay to determine the extent of NSF S-nitrosylation. Incubation
with WT Thorase, but not C137L Thorase, leads to the S-nitrosy-
lation of NSF (Figures 5C and 5D), reflecting the transfer of the
NO group from the C137 residue of S-nitrosylated Thorase to
NSF. However, S-nitrosylated NSF is not able to S-transnitrosy-
late Thorase (Figures 5E and 5F). Furthermore, a binding interac-
tion between the two proteins is required since an N-terminal
deletion of the first 100 amino acids (Thorase N100), which is still
S-nitrosylated, significantly reduces the interaction of Thorase
with NSF (Prendergast et al., 2014) and it abrogates the S-trans-
nitrosylation of NSF (Figures 5G and 5H).
We observe that adding ATPgS to purified WT, but not C137L
Thorase, causes a significant S-transnitrosylation of purified
NSF (Figures S2E and S2F). C91 is the S-nitrosylated residue
in NSF (Huang et al., 2005), and a mutation of C91 to serine




Figure 4. S-Nitrosylation-Dependent Interaction between Thorase, NSF, and PICK1
(A) Schematic diagram of recombinant Thorase pull-down from brain lysates to identify binding partners.
(B) Immunoblots of FPLC fractions of Thorase pull-down of protein complexes.
(C) Immunoblot analyses of Thorase, GluA2, NSF, and PICK1 IP from mouse whole-brain lysates in the presence of ATP with GSH or GSNO. The samples were
resolved on 10% SDS-PAGE and immunoblotted with anti-Thorase, anti-GluA2, anti-NSF, and anti-PICK1 antibodies.
(D) Normalized relative bound proteins in the IP samples (n = 3, p % 0.0001).
(E) Immunoblot analyses of GluA2 and phosphorylated GluA2 (GluA2 S880p) IP from mouse whole-brain lysates in the presence of ATPgS or ATP with GSH or
GSNO.
(F) Normalized relative bound proteins in the IP samples for (C) (n = 3, p % 0.0001).
(G) Coomassie stained SDS-PAGE analyses of GST-Thorase pull-downs of NSF in the presence of GSNO.
(H) Percentage of NSF bound to Thorase in (G) (n = 3, p = 0.0002).
(I) Immunoblot analyses of GST-GluA2C pull-downs of Thorase and NSF in the presence of GSH or GSNO. NSF was added to the prebound GluA2-Thorase
complex (GluA2/Thor +NSF), Thorasewas added to the preboundGluA2-NSF complex (GluA2/NSF + Thor), or Thorase andNSFweremixed together with GluA2
(GluA2C + NSF + Thor) during the GST-GluA2C pull-down experiments.
(J) Graphical representation of percentage of bound Thorase and NSF bound to GST-GluA2C for (I) (n = 3, p = 0.0139).
Means ± SEMs of the experiments performed. *p < 0.10, **p < 0.05, n.s. p > 0.10; ANOVA with Holm-Sidak post hoc test compared with WT; power: 1-b error
probability = 1.0).




(C91S) mutation abolishes the S-transnitrosylation, indicating
that NO group can transfer from C137 of Thorase to C91 of
NSF during the S-transnitrosylation process (Figures 5I, 5J,
S2G, and S2H). To directly examine Thorase S-transnitrosylation
of NSF in cells, we overexpressed NSF in HEK293 cells with or
without co-overexpression of WT Thorase and C137L Thorase.
The overexpression of WT Thorase leads to markedly elevated
levels of NSF S-nitrosylation after GSNO (50 mM) treatment (Fig-
ures S2I and S2J). The mutation of C137 also abrogates the ef-
fect of Thorase on the S-nitrosylation of NSF. The results also
suggest that C137L mutant is not nitrosylated in intact cells.
These results indicate that S-nitrosylated Thorase S-transnitro-
sylates NSF.
S-Nitrosylation of Thorase andTransnitrosylation ofNSF
Are Important for AMPAR-GluA2 Trafficking
To further evaluate the effects of S-nitrosylation of Thorase on
AMPAR trafficking, pH-sensitive GFP (pH-luorin) fused at the
N-terminal extracellular domain of GluA2 was used to examine
AMPAR distribution at the extracellular surface, as previously
described (Umanah et al., 2017; Zhang et al., 2011). Thorase
KO neurons were co-transfected with pH-GluA2 and mCherry
Ires or mCherry Ires Thorase WT or C137L mutant (Figures 6A
and S3). InWT neurons expressing pH-GluA2, NMDA-stimulated
internalization of GluA2 results in the loss of the fluorescent
signal for pH-GluA2, andwashout of NMDA leads to the recovery
of fluorescence (Figures 6B, 6C, and S3). NMDA induced a
significantly smaller reduction in pH-GluA2 fluorescence and
Figure 5. Thorase Transnitrosylates NSF
In Vivo upon NMDAR Activation
(A) Immunoblot analyses of NMDA-stimulated
S-nitrosylation of NSF in WT and Thorase KO
neurons. S-nitrosylation of NSF was assessed at
different times after NMDA treatment of neurons.
(B) Graphical representation of relative amount of
S-nitrosylated NSF (n = 3, p = 0.0111).
(C and D) Immunoblot analyses of trans-S-nitro-
sylation of NSF by S-nitrosylated Thorase WT (n =
3, p = 0.0106).
(E and F) Immunoblot analyses of trans S-nitro-
sylation of Thorase by S-nitrosylated NSF (n = 3,
p = 0.6964).
(G and H) Immunoblot analyses of trans S-nitro-
sylation of NSF by S-nitrosylated Thorase WT and
Thorase N-terminal deleted mutant, N100 (n = 3,
p = 0.0210).
(I and J) Immunoblot analyses of trans-S-nitro-
sylation of WT NSF but not C91S mutant by
Thorase (n = 3, p = 0.0208).
Means ± SEMs of the experiments performed, *p <
0.10, n.s. p > 0.10; ANOVA with Holm-Sidak post
hoc test compared with WT; power: 1-b error
probability = 0.85–1.0).
fluorescence recovery that is significantly
faster in Thorase KO control (vector)
than in WT neurons (Figures 6B and
6C), as previously described (Zhang
et al., 2011). However, in Thorase C137L
mutant neurons, NMDA stimulation leads to a significantly
reduced internalization of GluA2, and recovery is significantly
slower than in WT neurons. These results suggest that Thorase
S-nitrosylation is important for AMPAR-GluA2 internalization
and insertion into the synaptic membrane. Interestingly, NSF
S-nitrosylation is significantly decreased in Thorase KO neurons
following NMDAR stimulation (see Figures 5A and 5B). These re-
sults suggest that the absence of Thorase S-transnitrosylation of
NSF is reduced, resulting in a slower rate of AMPAR insertion to
the synaptic membrane. In nNOS KO neurons, NMDA stimula-
tion leads to a significantly reduced internalization of GluA2,
and recovery is significantly slower than in WT cultures (Figures
S4A–S4D), whereas in the presence of the NMDA antagonist
MK801 or the NOS inhibitor L-NAME, GluA2 internalization is
significantly reduced (Figures S4E–S4H). These results suggest
that endogenous S-nitrosylation of Thorase and NSF is NMDAR
and nNOS dependent and is critical for GluA2 trafficking.
NO Directly Influences Thorase-Mediated GluA2
Endocytosis
To evaluate the direct effect of the nitrosylation of Thorase on
GluA2 surface expression, we designed a live imaging assay us-
ing pH-GluA2 trafficking in HEK293 cells expressing functional
AMPARs. The addition of GSNO did not significantly affect the
intracellular pH as determined by the intracellular pH indicator
pHrodo Red AM, a fluorogenic probe (Figure S5A). HEK293 cells
were transfected with pH-GluA2, GRIP1, and WT Thorase or
C137L Thorase. At baseline, WT Thorase-transfected HEK293




cells show significantly lower levels of pH-GluA2 signal intensity
than vector control-transfected cells (Figures S5B and S5C).
Treatment with GSNO causes a further reduction in pH-GluA2
signal intensity in the setting of WT Thorase, but has a minimal
effect on pH-GluA2 signal intensity in cells transfected with
C137L Thorase.
Thorase and NSF Required for Proper GluA2 Surface
Expression
To assess the direct effects of Thorase and NSF nitrosylation on
GluA2 trafficking, we monitored the surface GluA2 expression in
real time in live HEK293 cells. HEK293 cells were co-transfected
with pH-GluA2, WT Thorase (mCherry), NSF, and GRIP1. The
addition of GSNO during live imaging stimulated the internaliza-
tion of pH-GluA2, resulting in the loss of fluorescent signal, and
the washout of GSNO leads to the recovery of the fluorescence
(Figures 6D and S6A). Interestingly, we observed different pat-
terns of the fluorescent signal for pH-GluA2 from different cells
in the same cultures treated with GSNO. The cells were therefore
immunostained to examine the expression of Thorase, NSF, and
GRIP1 (Figures S6A and S6B). The results suggest that control
cells that are not overexpressing Thorase and NSF have a signif-
icant loss of the fluorescent signal for pH-GluA2, and the
washout of GSNO leads to the recovery of fluorescence to base-
line (Figures 6D–6G). Cells overexpressing only Thorase (Thor-
ase OE) have loss of the fluorescent signal for pH-GluA2 more
than control cells; however, the washout of GSNO leads to
less recovery of fluorescence. Cells overexpressing NSF (NSF
OE) have loss of the fluorescent signal for pH-GluA2 lower than
control cells, and the washout of GSNO leads to the recovery
of fluorescence higher than baseline. Moreover, cells overex-
pressing both Thorase and NSF (Thorase/NSF OE) have loss of
the fluorescent signal for pH-GluA2 more than control cells,
and the washout of GSNO leads to the recovery of fluorescence
to baseline. Thus, both Thorase and NSF are required for proper
trafficking of GluA2.
S-Nitrosylation of Thorase Is Important for AMPAR-
Mediated Synaptic Plasticity
The surface GluA2 expression was also monitored in live
HEK293 cells co-expressing pH-GluA2 and NSF with WT Thor-
ase or the C137Lmutant. InWT cells, GSNO-stimulated internal-
ization of GluA2 results in the loss of the fluorescent signal for
pH-GluA2, and the washout of GSNO leads to the recovery of
fluorescence (Figures 6H–6J and S6C). GSNO induced a signif-
icantly smaller reduction in pH-GluA2 fluorescence and recovery
that is faster in control cells. However, in Thorase C137L mutant
cells, GSNO treatment leads to a significantly reduced internali-
zation of GluA2, and recovery is significantly slower than in WT
cells. Thorase interactions with GluA2 increase during NMDA-
induced endocytosis of GluA2 as expected; however, Thorase-
PICK1 interactions decrease during this process (Figures 6K
and S6D). These results suggest that direct NMDA-mediated
NO modification on Thorase is important for modulating GluA2
trafficking.
We next addressed whether long-term potentiation (LTP)
and long-term depression (LTD) are affected by the S-nitrosyla-
tion of Thorase. Adeno-associated viruses (AAVs) expressing
Figure 6. S-Nitrosylation of Thorase and
Transnitrosylation of NSF Are Important for
AMPAR-GluA2 Trafficking
(A) Time trace of pH-GluA2 fluorescence change in
response to NMDA in neurons expressingmCherry
empty vector or Thorase (WT or C137L mutant).
(B) Amplitudes of fluorescence intensity changes
(n = 5–7, p = 0.0367).
(C) Average recycling half-time (T1/2), the time
taken from maximum endocytosis to 50% re-
cycling (n = 5–7, p = 0.0299).
(D) Time trace of pH-GluA2 fluorescence change in
response to GSNO in HEK293 cells expressing
Thorase, NSF, and GRIP1.
(E) Amplitudes of fluorescence intensity changes
(n = 3–4, p % 0.0001).
(F) Average T1/2 (n = 3–4, p % 0.0001).
(G) Percentage of pH-GluA2 fluorescence recov-
ered after GSNO washout (n = 3–4, p % 0.0001).
(H) Time trace of pH-GluA2 fluorescence change in
response to GSNO in HEK293 cells expressing
Thorase WT or C137L.
(I) Amplitudes of fluorescence intensity changes
(n = 3, p = 0.0005).
(J) Average T1/2 (n = 3, p % 0.0115).
(K) Time trace of Thorase interactions (colocaliza-
tion) with GluA2 and PICK1 change in response to
NMDA in neurons (n = 4, p = 0.0001).
Means ± SEMs of the experiments performed. *p <
0.10, **p < 0.05, n.s. p > 0.10; ANOVA with Holm-
Sidak post hoc test compared withWT; power: 1-b
error probability = 0.85–1.0).




GFP-tagged WT or C137L Thorase-GFP were generated and in-
jected into the cortex of Thorase KOmice at postnatal day 2 (P2)
(KO-WT and KO-C137L), as described in our previous studies
(Umanah et al., 2017). AAVs expressing GFP alone were intro-
duced into Thorase WT and KO mouse brains at P2 as control
groups (WT-GFP and KO-GFP) (Figure S7). Two weeks after
infection, we prepared acute brain slices from injected mice
and performed extracellular field recordings from medial pre-
frontal cortex (mPFC) (Figure 7A).
The slope of the input-output (I/O) relationship was not
different among WT-GFP, KO-GFP, KO-WT, and KO-C137L
mouse slices (Figure 7B). LTPwas induced by a theta-burst stim-
ulation (TBS) protocol consisting of 5 trains of burst with 4 pulses
at 100 Hz, repeated 4 times at intervals of 10 s. Consistent with
previous results (Zhang et al., 2011), LTP was increased by the
deletion of Thorase (Figure 7C). Expression of Thorase WT in
Thorase KO mice rescued LTP (Figure 7C). Importantly, a signif-
icant increase in LTP was observed in KO-C137L slices
compared with WT-GFP slices (LTP magnitude at 40 min, WT-
GFP: 144.30% ± 5.92%, KO-GFP: 176.10% ± 7.75%, KO-WT:
134.50% ± 1.98%, KO-C137L: 173.10% ± 10.24%) (Figures
7C and 7D). Next, we compared the levels of LTD, which was
induced by a low-frequency train of 1 Hz for 15 min. LTD was
eliminated in KO-GFP as well as in KO-C137L slices (field excit-
atory post-synaptic potential [fEPSP] slope at 40 min after stim-
ulation, WT-GFP: 78.30% ± 3.30%, KO-GFP: 102.30% ±
4.29%, KO-WT: 82.22% ± 3.75%, KO-C137L: 97.22% ±
10.20%) (Figures 7E and 7F). These results imply that GluA2 traf-
ficking modulated by Thorase S-nitrosylation is essential for LTP
and LTD.
DISCUSSION
The major findings of this article are the observations that
Thorase is S-nitrosylated and that S-nitrosylated Thorase
S-transnitrosylates NSF to regulate GluA2 receptor trafficking.
Importantly, our data elucidate a mechanism underlying the
regulation of the internalization and insertion of AMPARs in the
postsynaptic membrane following NMDAR activation. The acti-
vation of NMDAR has been shown to enhance NO levels and
induce an increase in the S-nitrosylation of proteins (Choi
et al., 2000; Huang et al., 2005; Qu et al., 2012; Zorumski and
Izumi, 1998). The S-nitrosylation of Thorase at residue C137 in-
hibits ATP binding and ATPase activities, resulting in a stable
Thorase oligomeric complex. Thorase C137 is located within
the ATP hydrolysis motif next to the conservedWalker B residue,
E193. It is therefore not surprising that NO modification of the
ATP hydrolysis motif inhibits ATP hydrolysis, which augments
a stable oligomer formation similar to the ATP hydrolysis-defi-
cient Walker B mutant E193Q. The residue C137 is well
conserved among Thorase homologs, implying a broader effect
of S-nitrosylation on this family of enzymes. Oligomer formation
and stability play important roles in how AAA+ proteins assemble
and disassemble protein complexes (Kedzierska, 2006; Mogk
Figure 7. Thorase S-Nitrosylation-Modu-
lated GluA2 Trafficking Is Important for Syn-
aptic Plasticity
(A) Schematic representation of the prelimbic (PrL)
area in a coronal mPFC slice.
(B) Input-output relationships (I/O) of fEPSPs in
WT-GFP, KO-GFP, KO-WT, and KO-C137L slices.
Traces show representative fEPSPs obtained with
different stimulus intensities.
(C) LTP expression was dramatically increased in
KO-GFP and KO-C137L slices. Representative
traces show fEPSPs recorded at 5 min before
stimulation and 40 min after LTP induction (n = 6
slices from 6 mice; KO-GFP, n = 5 slices from 5
mice; KO-WT, n = 6 slices from 6mice; KO-C137L,
n = 6 slices from 6 mice).
(D) LTP magnitude was calculated at 5 min before
and 40 min after LTP induction as a percentage of
baseline responses (*p < 0.05).
(E) LTD was absent in KO-GFP and KO-C137L
mouse brain slices. Representative traces show
fEPSPs recorded at 5 min before stimulation and
40min after LTD induction (n = 6 slices from 6mice;
KO-GFP, n = 6 slices from 5 mice; KO-WT, n = 7
slices from 6 mice; KO-C137L, n = 8 slices from 6
mice).
(F) LTDmagnitude was quantified 40min after low-
frequency stimulation as a percentage of baseline
responses.
Values are means ± SEMs, *p < 0.05, ANOVA
with Holm-Sidak post hoc test compared with
WT-GFP.




et al., 2003; Sauer and Baker, 2011). Consistent with our previ-
ous study (Zhang et al., 2011), Thorase disassembles the
GluA2/GRIP1 complex in an ATP-dependent manner. However,
the disassembly of the GluA2/GRIP1 complex is markedly
impaired in the presence of NO. The formation of a stable
Thorase oligomer in the presence of NO accounts for the stable
Thorase/GluA2/GRIP1 complex. These findings suggest that the
S-nitrosylation of Thorase is critical in stabilizing Thorase-
AMPAR complexes.
Although several studies have shown that NSF participates in
the insertion of AMPARs, especially GluA2/GluA3, into the syn-
aptic compartment (Beretta et al., 2005; Huang et al., 2005; Ka-
tano et al., 2008; Steinberg et al., 2004) the mechanism of this
process is not completely understood. Previously, we showed
that NSF and Thorase exist together in the GluA2-containing
AMPAR complexes (Prendergast et al., 2014), and the present
study shows that NSF directly binds Thorase, suggesting that
these two proteins may function together to regulate AMPAR
trafficking. Both Thorase and NSF binding to GluA2 complexes
is influenced by S-nitrosylation. Thorase binding to GluA2 com-
plexes is augmented by S-nitrosylation via the inhibition of ATP
hydrolysis, whereas, S-nitrosylation-mediated increased NSF
binding affinity for GluA2 is not dependent on ATPase activity
(Huang et al., 2005). Our data show that increased S-nitrosyla-
tion of NSF upon NMDAR activation is dependent on interaction
with Thorase S-nitrosylation. Thorase S-nitrosylation occurs
earlier than S-nitrosylation of NSF upon NMDAR activation.
The S-nitrosylation of Thorase augments the Thorase interaction
with NSF, allowing Thorase to trans-nitrosylate NSF, thereby
increasing NSF S-nitrosylation and enhancing the NSF-medi-
ated insertion of GluA2 at the synapses. However, in the pres-
ence of Thorase-deficient S-nitrosylation mutant (C137L), NSF
S-nitrosylation is significantly reduced, resulting in the delayed
insertion of GluA2. Thus, C137L Thorase may act as a negative
regulator of NSF by delaying NSF S-nitrosylation and binding
to GluA2, thereby delaying the insertion of GluA2 at the synap-
ses. The data suggest that Thorase interaction and trans-nitrosy-
lation of NSF play a critical role in NSF-mediated insertion of
GluA2 at the synapses.
Nitrosylation has been shown to directly or indirectly influence
other proteins that regulate AMPARs. Our data further suggest
that S-nitrosylation of Thorase not only enhances endocytosis
of GluA2 but also influences the stability of the GluA2-PICK1
complex. Thus, S-nitrosylated Thorase may mediate GluA2-
PICK1 complex stability that is critical in retaining a pool of intra-
cellular AMPARs as well as delaying the recycling of AMPARs
during endocytosis. NSF regulates GluA2 recycling by binding
to the GluA2-PICK1 complex and dissociating PICK1 from
GluA2 (Hanley et al., 2002). In the absence of Thorase, the unsta-
ble GluA2-PICK1 in the intracellular pool allows NSF to bind the
free GluA2-containing AMPARs, thereby accelerating AMPAR
recycling and enhancing surface expression of AMPARs.
Although phosphorylation of GluA2 at S880 has been shown to
not be required for GluA2 endocytosis, it plays an important role
in the recycling of GluA2 during endocytosis (Lin and Huganir,
2007). GRIP1 is observed to associate more with the non-phos-
phorylated GluA2 complexes, whereas PICK1 associates more
with S880-phosphorylated GluA2 complexes, consistent with
previous reports (Lin and Huganir, 2007; Chung et al., 2000;
Kim et al., 2001). We also observed that NSF preferentially binds
to the non-phosphorylated GluA2 complex, whereas Thorase
shows no preference for S880-phosphorylated GluA2 com-
plexes or non-phosphorylated GluA2 complexes. The fact that
Thorase has similar binding affinity for both the phosphorylated
and non-phosphorylated GluA2 allows it to influence the
binding of GRIP1, NSF, and PICK1 to different states of GluA2
complexes. The differential binding of these proteins to GluA2
complexes is critical for modulating synaptic plasticity mediated
by AMPAR trafficking. We propose that Thorase may play an
important role in the differential binding of proteins that interact
with the GluA2-containing AMPAR complexes.
Our data suggest that Thorase may mediate GluA2-containing
AMPAR trafficking by (1) binding and internalizing GRIP1 with
non-phosphorylated GluA2 complexes, (2) retaining intracellular
GluA2 by stabilizing phosphorylated GluA2-PICK1 complexes,
and (3) inserting the GluA2 surface by enhancing NSF binding
to non-phosphorylated GluA2 complexes via trans-nitrosylation.
The present study and a previous study (Zhang et al., 2011) sug-
gest that Thorase plays important roles in both LTD and LTP. We
propose that decreased synaptic strength during LTD due to
a decrease in postsynaptic AMPAR surface expression is
mediated by Thorase-GluA2-GRIP1 endocytosis and the stabil-
ity of the retained intracellular Thorase-GluA2-PICK1 complex.
Conversely, increased synaptic strength during LTP due to
enhanced AMPAR surface expression is mediated by the
increased binding of NSF to GluA2-containing AMPARs as a
result of the interaction of NSF with Thorase.
Here, we provide evidence that NO modification of Thorase
and its association with AMPAR complexes play an important
role in AMPAR trafficking and synaptic plasticity. Overall, the
data presented in this study provide important information on
how NSF and PICK1 may be influenced by Thorase in regulating
the trafficking of AMPAR.
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R.N., Huganir, R.L., Dawson, T.M., Dawson, V.L., and Schnaar, R.L. (2014).
Ganglioside regulation of AMPA receptor trafficking. J. Neurosci. 34, 13246–
13258.
Qu, Z.W., Miao, W.Y., Hu, S.Q., Li, C., Zhuo, X.L., Zong, Y.Y., Wu, Y.P., and
Zhang, G.Y. (2012). N-methyl-D-aspartate receptor-dependent denitrosyla-
tion of neuronal nitric oxide synthase increase the enzyme activity. PLOS
ONE 7, e52788.
Sauer, R.T., and Baker, T.A. (2011). AAA+ proteases: ATP-fueled machines of
protein destruction. Annu. Rev. Biochem. 80, 587–612.
Steinberg, J.P., Huganir, R.L., and Linden, D.J. (2004). N-ethylmaleimide-sen-
sitive factor is required for the synaptic incorporation and removal of AMPA re-
ceptors during cerebellar long-term depression. Proc. Natl. Acad. Sci. USA
101, 18212–18216.
Tan, H.L., Queenan, B.N., and Huganir, R.L. (2015). GRIP1 is required for ho-
meostatic regulation of AMPAR trafficking. Proc. Natl. Acad. Sci. USA 112,
10026–10031.
Umanah, G.K.E., Pignatelli, M., Yin, X., Chen, R., Crawford, J., Neifert, S.,
Scarffe, L., Behensky, A.A., Guiberson, N., Chang, M., et al. (2017). Thorase
variants are associated with defects in glutamatergic neurotransmission that
can be rescued by Perampanel. Sci. Transl. Med. 9, eaah4985.
Zhang, J., Wang, Y., Chi, Z., Keuss, M.J., Pai, Y.M., Kang, H.C., Shin, J.H., Bu-
gayenko, A., Wang, H., Xiong, Y., et al. (2011). The AAA+ ATPase Thorase reg-
ulates AMPA receptor-dependent synaptic plasticity and behavior. Cell 145,
284–299.
Zorumski, C.F., and Izumi, Y. (1998). Modulation of LTP induction by NMDA re-
ceptor activation and nitric oxide release. Prog. Brain Res. 118, 173–182.






REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Monoclonal anti-Thorase NeuroMab Cat#75-157; RRID:AB_2290002
Extracellular anti-GluA2 NeuroMab Cat# 73-002; RRID:AB_10674575
Intracellular anti-GluA2 Abcam Cat# 3520-1 RRID:AB_10703317
anti phoshpo-S880 GluA2 Abcam Cat# ab52180; RRID:AB_880227
Monoclonal mouse anti-NSF Abcam Cat# ab16681; RRID:AB_2155806
Rabbit anti-PICK1 Abcam Cat# 3367-1; RRID:AB_10645748
Rabbit anti-GRIP1 Abcam Cat# ab44970; RRID:AB_732721
Rabbit anti-Biotin Abcam Cat# ab79111; RRID:AB_1603712
Goat polyclonal Biotin antibody conjugated to HRP Abcam Abcam Cat# ab53468 RRID:AB_867864)
Anti-rabbit IgG-HRP conjugate secondary Abcam Cat# ab98467; RRID:AB_10674445
Anti-mouse IgG-HRP conjugate secondary Abcam Cat# ab6823 RRID:AB_955395
Mouse anti-b-actin-HRP Sigma Cat#A3854; RRID: AB_262011
Donkey Anti-Rabbit IgG, Whole Ab ECL Antibody, HRP
Conjugated
GE Healthcare Cat#NA934; RRID: AB_772206
Sheep Anti-Mouse IgG, Whole Ab ECL Antibody, HRP
Conjugated
GE Healthcare Cat#NA931; RRID: AB_772210
Donkey Anti-Rabbit Alexa Fluor Plus 647 ThermoFisher (Invitrogen) Cat# A32795TR, RRID:AB_2866496
Donkey Anti-mouse Alexa Fluor Plus 350 ThermoFisher (Invitrogen) Cat# A10035, RRID:AB_2534011
Chemicals and Assay kits
Glutathione (GSH,) Millipore-Sigma Cat#PHR1359
S-nitrosoglutathione (GSNO,), Millipore-Sigma Cat#N4148
Nu-Nitro-L-arginine methyl ester (L-NAME,) Millipore-Sigma Cat#N5751
Dizocilpine (MK-801,) Millipore-Sigma Cat#M107
Glutaraldehyde solution Millipore-Sigma Cat# G7651
N-Methyl-D-aspartic acid (NMDA) Millipore-Sigma Cat# M3262
Adenosine 50-triphosphate (ATP) disodium salt hydrate Millipore-Sigma Cat#A2383
Adenosine 50-diphosphate (ADP) sodium salt Millipore-Sigma Cat#A2754
Adenosine 50-[g-thio]triphosphate (ATPgS) tetralithium salt Millipore-Sigma Cat#A1388
Neocuproine Millipore-Sigma Cat#N1501
EZ-Link HPDP-Biotin ThermoFisher Scientific Cat# 21341
1X PBS pH 7.4 Quality Biologicals Cat#114-058-101
10X TBS pH 7.4 Quality Biologicals Cat#351-086-101
Phosphatase inhibitor cocktail 2 Millipore-Sigma Cat#P5726
Phosphatase inhibitor cocktail 3 Millipore-Sigma Cat#P0044
Paraformaldehyde (PFA) reagent grade Millipore-Sigma Cat#P6148
Normal donkey serum Jackson ImmunoResearch Cat#017-000-121
pHrodo Red AM Intracellular pH Indicator ThermoFisher Scientific Cat# P35372
ADP Colorimetric Assay Kit ThermoFisher Scientific Cat#MAK081
PIERCE BCA PROTEIN ASSAY ThermoFisher Scientific Cat#23227
DreamTaq Green PCR Master Mix (2X) ThermoFisher Scientific Cat#K1082
Cell culture reagents
DMEM - Dulbecco’s Modified Eagle Medium ThermoFisher Scientific Cat#11965118
DMEM, no phenol red ThermoFisher Scientific Cat#31053028
FBS - fetal bovine serum ThermoFisher Scientific Cat#16000044
(Continued on next page)





REAGENT or RESOURCE SOURCE IDENTIFIER
Penicillin-Streptomycin ThermoFisher Scientific Cat#15140122
Neurobasal Medium ThermoFisher Scientific Cat#21103049
B-27 Plus Supplement (50X) ThermoFisher Scientific Cat#A3582801
Neurobasal Medium, minus phenol red ThermoFisher Scientific Cat#12348017
CTS TrypLE Select Enzyme ThermoFisher Scientific Cat#A1285901
Lipofectamine 2000 Reagent ThermoFisher Scientific Cat#11668019
Experimental Models: Organisms/Strains
Mouse: B6;129X1-ATAD11+/ Zhang et al., 2011.
Umanah et al., 2017
N/A
Mouse: C57BL/6J Jackson Laboratory JAX:000664
Oligonucleotides





Thorase C137S: 30 primer: GTTTTCCCAGAGCCCGGA
GGTCCATACAGGAG
IDT Oligo synthesis
Thorase C310S: 50 primer: CTCCTCTCTGTCAGGGA
ATATGTCAATTCTAC
IDT Oligo synthesis
Thorase C310S: 30primer: CCCTGACAGAGAGGAGG
GCAGCATCTCGAC
IDT Oligo synthesis
Thorase C137A: 50 primer: CCGGGCGCTGGGAAAA
CATTAATTGCCAAAGC
IDT Oligo synthesis
Thorase C137A: 30primer: GTTTTCCCAGCGCCCGG
AGGTCCATACAGGAG
IDT Oligo synthesis
Thorase C137L: 50 primer: CCGGGCCTCGGGAAAAC
ATTAATTGCCAAAGC
IDT Oligo synthesis
Thorase C137L: 30primer: GTTTTCCCGAGGCCCGG
AGGTCCATACAGGAG
IDT Oligo synthesis
Thorase C137V: 50 primer: CCGGGCGTCGGGAAAA
CATTAATTGCCAAAGC
IDT Oligo synthesis
Thorase C137V: 30primer: GTTTTCCCGACGCCCGG
AGGTCCATACAGGAG
IDT Oligo synthesis
Thorase C137N: 50 primer: CCGGGCAACGGGAAAAC
ATTAATTGCCAAAGC
IDT Oligo synthesis





pET32a EMD Biosciences Cat#69015-3
pGEX6P1 Amersham Cat#27-4597-01
pThorase-AAV-GFP This Manuscript N/A
pThorase- His6 This Manuscript N/A
pThorase-pLVX-IRES-mCherry Zhang et al., 2011.
Umanah et al., 2017
N/A
pThorase-Lenti-GFP Zhang et al., 2011.
Umanah et al., 2017
N/A
pCDNA-GRIP1 Zhang et al., 2011.
Umanah et al., 2017
N/A
pHluorin-GluA2 Zhang et al., 2011.
Umanah et al., 2017
N/A
pCDNA-NSF Huang et al., 2005 N/A
pET-NSF- His6 Huang et al., 2005 N/A
(Continued on next page)






Contact Valina L. Dawson (vdawson@jhmi.edu) for reagent and resource sharing.
Materials Availability
Plasmids and other materials generated in this study will be available upon request. Further information and requests for resources
and reagents should be directed to and will be fulfilled by the Lead Contact.
Data and Code Availability
Datasets is available to readers and there are no restrictions on any data or materials presented in this paper.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
All experimental procedures were according to the guidelines of Laboratory Animal Manual of the National Institute of Health Guide to
the Care and Use of Animals and were approved by the Johns Hopkins Medical Institute Animal Care and Use Committee. Thorase-
heterozygous C57BL/6J mice (ATAD1+/–) males and females generated in our previous studies (Umanah et al., 2017; Zhang et al.,
2011). For primary neuron cultures, three months old males and females Thorase-heterozygous C57BL/6J mice (ATAD1+/–) were
mated and the females were sacrificed at day 15-17 of pregnancy (E15-E17) to obtain Thorase-knockout (KO) C57BL/6J mice
(ATAD1-/–) and litter mates Thorase-wild-type C57BL/6Jmice (ATAD1+/+) pups. Genotyping of mice was carried out as we previously
described (Umanah et al., 2017; Zhang et al., 2011).
Cell Culture
HEK293 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) plus 10% (v/v) bovine serum (FBS) and 1% Penicillin-
Streptomycin, at 37Cwith a 5%CO2 atmosphere in a humidified incubator. Primary hippocampal and cortical neuron cultures were
prepared from embryonic day 15 (E15) and 17 (E17) mouse pups, respectively in neurobasal media with B27 supplement (GIBCO)
Continued
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Deposited Data
Raw data used for this study This Manuscript N/A
Software and Algorithms
ImageJ NIH https://imagej.nih.gov/ij/
Prism 6 GraphPad software https://www.graphpad.com/
scientific-software/prism/
ZEN lite Zeiss https://www.zeiss.com/microscopy/
us/products/microscope-software/
zen.html
PyMOL 3D structure viewer Schrödinger http://pymolwiki.org
Other
RIPA Lysis and Extraction Buffer Thermo Scientific Cat#89901
E. coli BL21(DE3) RIL cells Agilent Technologies Cat#230240
2X Lammli Sample Buffer Bio-Rad Cat#1610737
Novex WedgeWell 8-16% Tris-Glycine Mini Gels Thermo Scientific Cat#XP08165BOX
SUPERSIGNAL WEST PICO PLUS Thermo Scientific Cat#34580
Blotting-Grade Blocker, nonfat dry milk Bio-Rad Cat#1706404
Restore western blot stripping buffer Thermo Scientific Cat#21059
Nitrocellulose Membrane Bio-Rad Cat#1620115
X-ray film RPI Cat#248300
Hamilton GASTIGHT syringe, 1700 series Sigma Cat#20972
Pierce High Capacity Endotoxin Removal Spin Column Thermo Scientific Cat#88276
Superdex 200 Increase 10/300 G GE Healthcare Cat#45-002-570
Ni Sepharose 6 Fast Flow GE Healthcare Cat#17-5318-06




and 1% Penicillin-Streptomycin as previously described (Umanah et al., 2017). Transfections were performed with Lipofectamine
2000 Reagent (Invitrogen) according to the manufacturer’s instruction.
Recombinant proteins
All recombinant proteins were expressed in E. coli BL21(DE3) codon plus and induced by 1.0 mM isopropyl thiogalactoside (IPTG) at
16C overnight. The bacterial pellets were lysed using a microfluidizer (Microfluidics) in binding/ATPase buffer (100 mM Tris-HCl pH
7.5, 150 mM NaCl, 5 mM MgCl2, and 5% Glycerol) with protease inhibitors (Sigma) and centrifuged at 15,000 3 g for 30 min. His-
tagged and GST-tagged proteins were purified by using Nickel-NTA and glutathione beads, respectively following manufacturer’s
instructions. Protein samples eluted from the beads were further purified by size exclusive chromatography (GE Healthcare) using
the ATPase buffer. The purity of the recombinant proteins was checked by Coomassie staining and western immunoblotting.
METHOD DETAILS
ATPase Activities
The ATPase activities of all Thorase mutants generated in this study along side wild-type were examined by ATP binding and hydro-
lysis assays. The ATP binding was evaluated by photolabeling technique as described by Babst et al. (Babst et al., 1998) with some
few modifications. Briefly, 20 mL of purified Thorase protein samples (5 mg) in ATPase buffer were incubated at 4C with 20 mCi of
[a-32P]ATP (2000 Ci/mmol)]. The mixtures were then illuminated by UV light to cross-link the bound [a-32P]ATP to the bound proteins.
The protein samples were then precipitated by adding trichloroacetic acid (TCA), washed with acetone and resuspended in 1x
laemmli sample buffer (Bio-Rad). The samples were resolved on SDS-PAGE, stained with Coomassie blue to check protein input
and exposed to a phosphor screen (Perkin Elmer, USA). Quantitation of [a-32P] ATP labeled protein was performed by scanning
the radioautograph with a soft laser scanning densitometer.
The ATP hydrolysis activity was determined by using the ADP Colorimetric Assay Kit (Sigma) following manufacturer’s instruction
with some modifications. Briefly, the recombinant proteins (2.0 ug) were incubated with 100 mM ATP for 30 min at 37C for ATP hy-
drolysis to ADP. To check ATP degradation to ADP that were not due to enzymatic hydrolyses the ATPase buffer (without protein)
containing 100 mM ATP was included as control. The samples were incubated with ADP reaction mix buffer for 30 min at room tem-
perature in the dark and the absorbances at 570 nm for each sample (in triplicates) were measured to determine amount of ADP pre-
sent in the samples. The rate of ATP hydrolysis was determined by the rate of ADP formation.
The 3D structure modeling of Thorase full length and AAA ATPase domain were generated by the SWISS-MODEL (Arnold et al.,
2006) and confirmed by Phyre2 (Kelley et al., 2015) protein modeling. All images obtained were viewed and labeled with Pymol
pdb viewer.
Biotin Switch Method (S-nitrosylation and site identification)
The biotin switch method was performed as previously described (Jaffrey et al., 2001; Jaffrey and Snyder, 2001) with some modifi-
cations. Briefly, cell lysates or recombinant proteins were prepared in NP40/HEN buffer (250 mM HEPES, 1 mM EDTA, 0.1 mMNeo-
cuproine, 0.5% Nondiet P-40). Blocking buffer (2.5% SDS, 10 mMmethyl methane thiosulfonate [MMTS] (Thermo Scientific) in HEN
buffer [250 mM HEPES, 1 mM EDTA, 0.1 mM Neocuproine]) was mixed with the samples and incubated for 20 min at 50C with
frequent vortexing to block free thiol groups. After removing excess MMTS by spin columns, newly formed thiols were linked with
sulfhydryl-specific biotinylating reagent through incubation with 5 mM ascrobate and 0.4 mMN-[6-(biotinamide)hexyl]-30-(20-pyridyl-
dithio)propionamide (Biotin-HPDP, Thermo Scientific) for 1 h at room temperature with rotation. Unreacted Biotin-HPDP was
removed by acetone precipitation and centrifugation, and the pellet was resuspended in 100 ml HENS buffer (HEN buffer plus
1.0% SDS). Two volumes of neutralization buffer (250 mM HEPES, 100 mM NaCl, 1 mM EDTA, and 0.5% Triton X-100) were added,
and the solution was cleared by centrifugation in order to pellet the undissolved debris. The biotinylated proteins were pulled-down
with Neutravidin-agarose beads (Thermo Scientific) from the remaining supernatant. Pellets were then washed 5 times with neutral-
ization buffer plus 0.6 M NaCl and eluted by SDS sample buffer and subjected to western blot analysis.
S-Nitrosylation of either Thorase or NSF in cultured primary cortical neurons was assayed as described above, except that neurons
were treated with NMDA (20 mM) and glycine (10 mM) in Tyrodes’ solution (119 mM NaCl, 5 mM KCl, 25 mM HEPES, 2 mM CaCl2,
300 mM MgCl2, and 1 mM TTX) for 5 min at 37
C in the dark in the presence or absence of MK801 (10 mM) or L-NAME (300 mM)
for 30 min before NMDA stimulation.
For the S-transnitrosylation assay, purified recombinant Thorase (0.1 mg/ml) or NSF (0.1 mg/ml) bound to beads was incubated with
GSNO (100 mM) for 1 h at room temperature in the dark. The beads were then washed with HEN buffer (without GSNO) and the SNO-
proteins were then used as NO donors for 1 h at room temperature in the dark in order to test for potential S-transnitrosylation of
recombinant Thorase or NSF. The protein samples were then subjected to the biotin switch assay as described above to monitor
S-transnitrosylation of each protein.
Detailed protocols for the identification of site-specific S-nitrosylation using organic mercury resin assisted capture approach have
been published (Doulias et al., 2010, 2013). In brief, free thiols on recombinant S-nitrosylated Thorase were blocked with incubation
with 35mMmethyl methane thiosulfonate [MMTS] (Thermo Scientific) for 30min at 55Cwith frequent vortexing. The Thorase protein
suspension was then loaded onto pre-activated organic mercury resin-containing columns for 60min at room temperature. Upon the




completion of the reaction, the column was extensively washed to eliminate nonspecific interactions. Bound Thorase was subjected
to on column trypsin digestion overnight at room temperature. Unbound peptides were removed by extensive washes and cysteine-
containing peptides were eluted with performic acid for 45 min according to published protocols. The performic acid released pep-
tides were analyzed by mass spectrometry (Doulias et al., 2010; Doulias et al., 2013).
Thorase mediated disassembly of GluA2/GRIP1 assay
The effect of nitrosylation on Thorase disassembling of GluA2-GRIP1 complex was examined by immunoprecipitating GluA2 from
isolated mouse hippocampi lysate as previously described with some modification (Umanah et al., 2017; Zhang et al., 2011). Briefly,
freshly mouse hippocampi were homogenized in binding buffer (25 mM HEPES-KOH (pH 7.8), 150 mM NaCl, 3 mM MgCl2, 1 mM
DTT) containing protease inhibitors. Triton X-100 was added to a final concentration of 1% and incubated at 4C (with mixing by
end-to-end rotation) for 1 hour. Samples were centrifuged at 15,000 x g for 30 min and supernatant was incubated with Dynabead
(Invitrogen) pre-bound with anti-GluA2 antibodies plus 2 mM ADP or ATP or ATPgS at 4C (with mixing by end-to-end rotation) for 1
hour. The samples were then transferred to room temperature and incubated with 100 mMGSH or GSNO (with mixing by end-to-end
rotation) for 1 hour. Beads were washed 3 times with binding buffer plus 100 mMGSH or GSNO (with mixing by end-to-end rotation)
for 2 minutes per wash. After the last wash beads were resuspended in 1x laemmli sample buffer, resolved on 10% SDS-PAGE and
immunoblotted using anti-GluA2, anti-Thorase and anti-NSF antibodies.
Oligomer formation assays
To evaluate the oligomer formation of Thorase, purified recombinant proteins (5 mg in 100 ml) were treated with 5 mM ADP or ATP in
modified HEN buffer (250 mM HEPES, 2 mM MgCl, 0.1 mM Neocuproine, 0.5% Nondiet P-40) containing 100 mM GSH or GSNO at
4C to minimize ATP hydrolysis for 1 hour. Oligomer formation upon ADP or ATP binding was examined by chemical cross-linking
with 0.02%glutaraldehyde at room temperature for 5minutes as previously described (Babst et al., 1998). The cross-linked products
were TCA-precipitated, washed with acetone and analyzed by SDS–PAGE and Immunoblotted with anti-Thorase antibody.
Coimmunoprecipitation and GST and His6 Pull-Down Assays
Wholemouse brains homogenized in ATPase buffer containing protease inhibitors plus 1%Triton X-100 were centrifuged at 15,000 x
g for 30 minutes. Approximately 2 mM of ATPgS with 100 mM GSH or GSNO was added to the supernatant and incubated with
magnetic-Dyna-beads (Invitrogen) pre-bound to anti-Thorase, anti-GluA2, anti-NSF or anti-PICK1 antibodies at 4C for 3 hours
with end-over-end mixing. The beads were washed 3 times with ATPase buffer plus ATPgS with GSH or GSNO and resuspended
in 1x laemmli sample buffer. Proteins bound to the beads were detected by immunoblotting using anti-Thorase, anti-GluA2, anti-
NSF and anti-PICK1 antibodies.
For all GST and His6 pull-down experiments purified recombinant GST or His6 fusion proteins bound to glutathione (GST) or His-
Nickel affinity beads, respectively were mixed with corresponding binding protein partners in ATPase buffer containing 2 mMADP or
ATP or ATPgS and incubated at 4C for 2 hours and then additional 1 hour incubation at room temperature with 100 mM GSH or
GSNO. The GST or His-Nickel beads were washed 4 times ATPase buffer with GSH or GSNO and samples resolved on 10%
SDS-PAGE. The bound proteins were detected by Immunoblotting using corresponding antibodies.
GluA2 recycling assays
GluA2 surface expression recycling assay was carried out as previously described (Lin and Huganir, 2007; Zhang et al., 2011). Hip-
pocampal neurons were cultured from postnatal day 0 mice obtained by mating heterozygote parents (Thorase KOmice). Mice were
genotyped by PCR. Neurons from homozygous Thorase knock-out, homozygous knock-out nNOS and wild-type mice littermates
were transfected with plasmids on day in vitro (DIV) 15 and imaging experiments were performed on DIV 18–20 using a Zeiss
LSM 5 Duo confocal microscope as described previously (Lin and Huganir, 2007; Zhang et al., 2011). Briefly, pHluorin-GluA2
(GluA2-GFP) and mCherry were imaged with 488 nm and 560 nm excitation, respectively. Neurons were continuously perfused at
a rate of 1 ml/min in recording buffer (25 mM HEPES, pH = 7.4, 120 mM NaCl, 5 mM KCl, 2.5 mM CaCl2, 1.5 mM MgCl2, 30 mM
glucose, and 1 mM TTX). Prior to perfusion with NMDA, images were collected for 5 min (1 image/min) to establish a baseline (F0)
in the recording buffer with or without MK801 or L-NAME. The NMDA solution contained 300 mM MgCl2, 10 mM glycine, and
20 mM NMDA. After 5 min perfusion with the NMDA solution, neurons were continuously perfused for 60 min with recording
buffer to monitor fluorescence changes. Images were analyzed using NIH ImageJ software (Rasband, W.S., NIH, https://imagej.
nih.gov/ij/, 1997–2007).
Nitrosylation mediated recycling of GluA2 surface expression in HEK293 cells
Real-Time Imaging of surface expression of pH-luorin-GluA2 (GluA2-GFP) in HEK293 cells was carried out as previous described by
Huang et al. (Huang et al., 2005) with some modifications. To determine if whether treatment of GSNO affects intracellular pH, intra-
cellular pH indicator, pHrodoTMRed AM (Life Technologies, USA) was incubated in the HEK293 cells for 30min in Live-cell imaging
buffer, Hank’s balanced salt solution (HBSS) without phenol red (Life technologies). Following dye loading, the cells were subjected




to live cell imaging using. The fluorescence signals were monitored by time-lapse recording with perfusion at a rate of 1 ml/min in
HBSS for 10 minute to establish a baseline followed by perfusion with 0.5 mM GSNO in HBSS for 4 minutes and then continuously
perfused with HBSS for another 30 minutes.
For real-time imaging of surface expression of pHluorin-GluA2, HEK293 cells were plated on 35 mm dishes with a glass coverslip
and co-transfected with pHluorin-GluA2 (GluA2-GFP), mCherry ires Thorase (wild-type or C137L), GRIP1 and NSF. Prior to imaging,
culture mediumwas replaced with HBSS. Cells expressing pHluorin-GluA2 (GluA2-GFP) andmCherry were imaged with 488 nm and
560 nm excitation, respectively. The Fluorescence signals were monitored by time-lapse recording with an interval of 1 minute for
4 minutes using a Zeiss LSM 5 Duo confocal microscope. Cells were perfused at a rate of 1 ml/min in HBSS for 4 minutes to establish
a baseline followed by perfusion with 0.5 mM GSNO in HBSS for 4 minutes and then continuously perfused with HBSS for another
16 minutes. Images were analyzed using NIH ImageJ software (Rasband, W.S., NIH, https://imagej.nih.gov/ij//, 1997–2007).
For Immunostaining of HEK293 cells co-epressing pHluorin-GluA2, Thorase (Ires mCherry), NSF and GRIP1, cells were
treated with 0.5 mM GSH or GSNO in HBSS for 2 minutes and then fixed with 4% PFA in PBS (pH 7.5) plus 0.1 mM GSH or
GSNO for 15 minutes. The cells were immunostained with mouse monoclonal anti-NSF and rabbit monoclonal anti-GRIP1. Stained
NSF and GRIP1 were visualized by using anti-mouse Alexa 350-conjugated and anti-rabbit Alexa 647-conjugated secondary anti-
bodies (Invitrogen), respectively. Imaging of cells was performed using a Zeiss LSM 5 Duo confocal microscope. All images were
analyzed using NIH ImageJ software (Rasband, W.S., NIH, https://imagej.nih.gov/ij/, 1997–2007).
Electrophysiology
To express Thorase-C137L in mouse brain approximately 2 mL AAV2 GFP or Thorase-GFP wild-type, or C137L (1X1013 GC/ml,
Vector BioLabs) were injected into both sides of intracerebroventricular of the newborn (postnatal day 1) Thorase wild-type of
knockout mice as previously described (Umanah et al., 2017). The expressions of GFP or Thorase-GFP were checked by immuno-
histochemistry and after 14 days.
Mice expressing GFP or Thorase-GFP were sacrificed at P16-18 and brains were rapidly placed into cold artificial cerebrospinal
fluid (ACSF) containing (in mM): NaCl 125, KCl 2.5, MgSO4 1.0, NaH2PO4 1.2, NaHCO3 26, CaCl2 2.0, and D-glucose 10. Coronal
cortical slices (350 mm) were prepared and incubated in ACSF infused with 95% O2/5% CO2 for recovery at 32
C for 30 min. After
another 30 min of equilibration at room temperature, slices were transferred into a submerged recording chamber and perfused
continuously with 28-30C oxygenated ACSF at a rate of 2 ml/min. All experiments were conducted in accordance with the National
Institutes of Health guidelines for the care and use of animals, and all procedures were approved by Harvard Medical Area Standing
Committee on Animals.
Extracellular recordings of field excitatory postsynaptic potentials (fEPSPs) were performed using HEKA EPC10 amplifier (HEKA
Elektronik, Lambrech, Germany). Picrotoxin (100 mM) was routinely added to the perfusion solution to block GABAA receptor-medi-
ated inhibitory synaptic responses. Presynaptic stimuli (0.1 Hz, 100 ms) were delivered at the border of layer I and layer II/III with a
concentric electrode (FHC), and fEPSPs were obtained using a glass microelectrode filled with 1 M NaCl placed at Layer V. After
20 min of stable baseline recording, LTP was triggered using a theta-burst stimulation (TBS) protocol consisting of five trains of burst
with four pulses at 100 Hz, at 200-ms interval, repeated four times at intervals of 10 s. For LTD studies, 1 Hz stimulation was applied
for 15 min. The magnitude of LTP or LTD was calculated at 40 min after stimulation as a percentage of baseline responses (Umanah
et al., 2017). Data were acquired by PatchMaster software (HEKA Elektronik, Lambrech, Germany), sampled at 10 kHz, filtered at 2.9
kHz, and analyzed using Clampfit 10.5 software (Molecular devices, Palo Alto, CA, USA).
QUANTIFICATION AND STATISTICAL ANALYSIS
Western blots were visualized using either the SuperSignal West ECL system from Pierce followed by film exposure or the LI-COR
Odyssey infrared imaging system. The images were quantified using NIH-ImageJ software. Data are expressed asmean ± SEM from
the indicated number of experiments. All experiments were repeated at least three times and quantitative data are presented as the
mean ± standard error of the mean (SEM) performed by GraphPad prism6 software (Instat, GraphPad Software). Statistical signifi-
cance was assessed by one-way or two-way ANOVA or Two-tailed paired t-Test. The significant differences were identified by post
hoc analysis using the Holm-Sidak post hoc method for multiple comparisons. Assessments were considered significant with a
p < 0.05 and non-significant with a p > 0.05. Power analysis and sample size calculation for all experiments were determined using
G*Power 3.1 statistics software (Table S1).
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